Stock comparison
Moderna, Inc. is 1.8x more valuable than BIOGEN INC. by market capitalization ($57.75 B vs $32.60 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 1.8x more valuable than BIOGEN INC. by market capitalization ($57.75 B vs $32.60 B).
Market value leader
MRNA
Moderna, Inc. is 1.8x more valuable than BIOGEN INC. by market capitalization ($57.75 B vs $32.60 B).
Revenue leader
BIIB
MRNA: $1.94B vs BIIB: $9.89B.
Profit leader
BIIB
MRNA: -$2.82B vs BIIB: $1.29B.
Margin leader
BIIB
MRNA: -145.2% vs BIIB: 13.1% net margin.
| Metric | MRNA | BIIB |
|---|---|---|
| Market cap | $57.75 B | $32.60 B |
| US-listed rank | #290 | #448 |
| Revenue (latest FY) | $1.94B | $9.89B |
| Net income (latest FY) | -$2.82B | $1.29B |
| Net margin | -145.2% | 13.1% |
| P/E (trailing FY) | - | 25.2x |
| SEC filings | 1,447 | 2,692 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 1.8x more valuable than BIOGEN INC. by market capitalization ($57.75 B vs $32.60 B).
In their latest fiscal years, Moderna, Inc. reported $1.94B in revenue while BIOGEN INC. reported $9.89B.
Full pages: Moderna, Inc. and BIOGEN INC., or browse the full rankings.